Tacrolimus confers lower acute rejection rates and better renal allograft survival compared to cyclosporine

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 6, Issue 4

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Transplantation

ISSN

2220-3230

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Transplant. Dec 24, 2016; 6(4): 697-702
Published online Dec 24, 2016. doi: 10.5500/wjt.v6.i4.697

Table 5 Graft loss n (%)

Parameter	Tacrolimus n = 106	Cyclosporine n = 123	P-value
Death with functioning graft	61 (58)	66 (54)	0.55
Cause of death			0.85
Cardiovascular disease	19 (18)	19 (15)
Infections	10 (9)	9 (7)
Malignancy	10 (9)	9 (7)
Others	33 (31)	41 (33)
Causes of graft loss			0.44
Chronic allograft nephropathy	18 (17)	29 (24)
Acute rejection	14 (13)	11 (9)
Acute on chronic rejection	8 (8)	13 (11)
Recurrent disease	1 (1)	1 (1)
Death	63 (59)	68 (55)
Component of non- adherence	15 (14)	20 (16)	0.65
Component of underimmunosuppression	21 (20)	25 (20)	0.92

Citation: Kamel M, Kadian M, Srinivas T, Taber D, Posadas Salas MA. Tacrolimus confers lower acute rejection rates and better renal allograft survival compared to cyclosporine. World J Transplant 2016; 6(4): 697-702
URL: https://www.wjgnet.com/2220-3230/full/v6/i4/697.htm
DOI: https://dx.doi.org/10.5500/wjt.v6.i4.697

Kamel M, Kadian M, Srinivas T, Taber D, Posadas Salas MA. Tacrolimus confers lower acute rejection rates and better renal allograft survival compared to cyclosporine. World J Transplant 2016; 6(4): 697-702 [PMID: 28058220 DOI: 10.5500/wjt.v6.i4.697]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.